par Reardon, David D.A.;Dresemann, Gregor;Taillibert, Sophie;Campone, Mario;van den Bent, Martin M.J.;Clement, Paul M J P.;Blomquist, Erik;Gordower, Laurence 
;Schultz, Henrik;Raizer, Jeffrey;Hau, Peter;Easaw, Jacob;Gil, Miguel;Tonn, Jörg Christian J.;Gijtenbeek, Anja M M A.;Schlegel, Uwe;Bergstrom, Per;Green, Sylvan S.B.;Weir, Alva Bowen A.;Nikolova, Zariana
Référence British Journal of Cancer, 101, 12, page (1995-2004)
Publication Publié, 2009-12
;Schultz, Henrik;Raizer, Jeffrey;Hau, Peter;Easaw, Jacob;Gil, Miguel;Tonn, Jörg Christian J.;Gijtenbeek, Anja M M A.;Schlegel, Uwe;Bergstrom, Per;Green, Sylvan S.B.;Weir, Alva Bowen A.;Nikolova, ZarianaRéférence British Journal of Cancer, 101, 12, page (1995-2004)
Publication Publié, 2009-12
Article révisé par les pairs
| Résumé : | Background: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). Methods: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS). Results: The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%). Conclusions: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity. © 2009 Cancer Research UK. |
